Prostamax 20 mg: Prostamax is a short-peptide catalogue designation. Analytical evaluation starts by resolving what the catalogue name represents in the supplied material. Sequence-defined short peptides, chemically modified analogues and heterogeneous mixtures require different reference strategies; they should not inherit numerical chemistry simply because their product titles look similar. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

PEG-MGF 4mg: PEG-MGF is a PEG-associated mechano-growth-factor-related peptide designation. Analytical evaluation starts by resolving what the catalogue name represents in the supplied material. Sequence-defined short peptides, chemically modified analogues and heterogeneous mixtures require different reference strategies; they should not inherit numerical chemistry simply because their product titles look similar. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

5-Amino-1MQ 5 mg: 5-Amino-1MQ is a small-molecule research designation for 5-amino-1-methylquinolinium-related material. It is not a peptide. The quinolinium species and a supplied salt, such as a specified counterion-containing form, must be distinguished when interpreting formula and molecular-weight information. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

CJC-1295 + DAC 5mg: CJC-1295 DAC identifies a growth-hormone-releasing-hormone-related peptide with a drug-affinity-complex modification. The conjugating group is part of the chemical identity and distinguishes it from a peptide sold without DAC. Reference selection must therefore account for the modification rather than using only a shortened peptide name. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

GHRP-6 10mg: GHRP-6 is a synthetic hexapeptide described in growth-hormone-secretagogue research. Its six-residue structure and stereochemical composition provide a defined basis for analytical characterisation. It should be identified as its own compound rather than treated as a generic synonym for all growth-hormone-releasing peptides. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

Thymosin alpha 1 5mg: Thymosin alpha-1 is an N-terminally acetylated peptide also associated with the name Thymalfasin. Its sequence and acetylation are part of the reference chemical identity. It is distinct from thymosin beta-4-related materials and from mixed tissue-derived peptide preparations. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

SS-31: SS-31, also known as Elamipretide, is a synthetic tetrapeptide containing non-standard residue chemistry. It is studied in mitochondrial membrane and biochemical research systems. Its modified small-peptide structure requires an exact chemical reference rather than an assumption based on standard amino-acid composition alone. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

IGF-1LR3 1mg: IGF-1 LR3 is a modified insulin-like-growth-factor-I designation. The LR3 specification includes an extended amino-terminal region and a residue substitution relative to the parent reference. Those structural features distinguish it from unmodified IGF-1 and from the DES form. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

PT-141 Bremelanotide 10mg: PT-141 is the research designation associated with Bremelanotide, a cyclic peptide studied in melanocortin receptor systems. Its cyclic structure and chemical modifications distinguish it from other melanocortin-related peptides. Reference selection should preserve the full compound identity rather than relying on a category description. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.

KPV 10mg: KPV is the tripeptide Lys-Pro-Val, a short sequence associated with the C-terminal region of alpha-melanocyte-stimulating hormone. Its three-residue identity distinguishes it from the full-length parent peptide and from cyclic melanocortin analogues. It can be characterised as a defined small peptide. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.